06Jun

Aspirin appears to boost the survival rate for older people with bladder and breast cancer.

“[Increased survival] was primarily strongest amongst those who took aspirin 3 or more times a week,” said Holli Loomans-Kropp, PhD, MPH, study author and NCI DCP Cancer Prevention Fellow at the National Cancer Institute. Her comments appear in Oncology Nursing News.

Researchers used data collected over an 8-year period from 139,896 participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. They found taking aspirin had no effect on whether a person would develop cancer. Nor did it have any impact on survival rates for those with esophageal, gastric, pancreatic, or uterine cancer.

But for those patients 65 years and older with breast or bladder cancer, taking aspirin three or more times a week improved their chances of survival over those taking no aspirin or taking it less often.

In the study, published online last month in JAMA Network Open, the researchers, said, “Although aspirin use at least 3 times/week was associated with the strongest risk reduction, any aspirin use was associated with increased bladder and breast cancer survival. These results may indicate that for some cancer types, any aspirin use may be advantageous; however, greater benefit may be observed with increased frequency of use.”

The researchers note that many people – between 25% and 50% of adults – take aspirin regularly. “Long-term aspirin use has been associated with decreased risk of heart disease, stroke, cancer (particularly gastrointestinal cancers), and all-cause mortality,” the researchers write. “Recent research suggests that aspirin use may offer protection against the development of and mortality from other cancer types as well.”

Previous findings from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial showed an association between aspirin use and significant reductions in the risk of colorectal polyps and colorectal cancer, but minimal or no association with prostate and ovarian incidence and survival.

“Although prior research has been most heavily concentrated in gastrointestinal cancers, our analysis extends the advantages associated with aspirin use to other cancers, such as bladder and breast cancers,” the researchers write. The latest study now suggests that aspirin use can improve longevity for older people with breast cancer and especially for bladder cancer.

“There is definitely evidence provided by our study, but it is not enough to suggest anything clinical, as it was a secondary analysis,” Loomans-Kropp told Oncology Nursing News. “Other randomized clinical trials are required to be able to say anything more definitively.”

[bdp_post_carousel]

author avatar
Green Key
Jun 6, 2023

Statins Show Promise in Reducing Death from Ovarian Cancer

Women with ovarian cancer who take statins to lower their cholesterol have a 40% lower death rate.

“These drugs are appealing as they are widely used, inexpensive, and well tolerated in most patients. The associated reduction in ovarian cancer mortality is promising,” said Dr. Kala Visvanathan, lead researcher of a new study presented last week during the American Association for Cancer Research Virtual Annual Meeting II.

Dr. Visvanathan, professor of epidemiology and oncology at Johns Hopkins Bloomberg School of Public Health and Sidney Kimmel Comprehensive Cancer Center in Baltimore, said all statins reduced the risk of dying, with lipophilic statins such as simvastatin and lovastatin, decreasing the likelihood by an average 43%. The most significant reductions occurred in those with high-grade serous carcinoma (40% reduction in mortality) and endometrioid ovarian cancer (50% reduction.)

The findings are the most comprehensive to date and add support to other, smaller studies showing similar improvements in ovarian cancer mortality from statins.

Most recently, a team of researchers at Australia’s QIMR Berghofer Medical Research Institute, analyzed 36 studies of several common medications taken by ovarian cancer patient. They concluded statin use showed the most promise. “Statin use is associated with better ovarian cancer survival,” they wrote in an article this month in Gynecologic Oncology, cautioning that, “Further study, preferably a clinical trial, is required.”

At the AACR meeting, Visvanathan said her team reviewed data on 10,062 ovarian cancer patients from the Finnish national cancer registry. 2,621 used statins, and 80% of those used lipophilic statins.

“Our results provide further evidence in support of the clinical evaluation of lipophilic statins as part of the treatment of ovarian cancer,” Visvanathan said.

Ovarian cancer is a rare cancer type, accounting for only about 1.2% of cancer cases diagnosed in the United States each year. Its five year survival rate is less than 50% because of the difficulty of diagnosing it until it has progressed to an advanced stage.

[bdp_post_carousel]

author avatar
Green Key
Jun 6, 2023

Recognizing Nursing Assistants This Special Week

This week – Nursing Assistants Week — we at Green Key Resources want to extend a special thank you to the nation’s certified nursing assistants and recognize the vital work they do.

These are the professionals who do the day-to-day work of caring for patients too ill, too elderly or who are just in need of extra help as they recover.

Never before has so much been asked of the 1.6 million women and men working in nursing and care facilities and hospitals all across the country. Risking their own health, they’ve worked alongside doctors and RNs to care for COVID-19 patients, bathing, turning and feeding those who need the help and answering their calls.

In other times, this work is part of their daily routine. This year, it is heroic work.

Thank you for being there. We appreciate what you do for all of us.

[bdp_post_carousel]

author avatar
Green Key